|
Clinical study | MSC type | Cardiac disease | Modification | Applied cell number | Route of administration | Time of MSC application after MI | Effect on LVEF |
|
POSEIDON [233] | Bone marrow MSCs (allogenic versus autologous) | Nonischemic dilated cardiomyopathy | | 1 × 108 | Transendocardial | | No change |
RIMECARD [234] | Umbilical cord MSCs versus bone marrow MSCs (allogenic) | Dilated cardiomyopathy | | 1 × 106/kg | Intravenously | | Improved |
PROMETHEUS [15] | Bone marrow MSCs (autologous) | Chronic ischemic cardiomyopathy | | 2 × 107–2 × 108 | Intramyocardial | | Improved |
MSC-HF [235] | Bone marrow MSCs (autologous) | Ischemic heart failure | | ~8 × 107 | Intramyocardial | | Improved |
C-CURE [133] | Bone marrow MSCs (autologous) | Chronic heart failure | Preconditioning with cardiogenic cytokines | 7 × 108 | Endoventricular | | Improved |
Xiao et al. [236] | Bone marrow MSCs versus bone marrow MNCs (autologous) | Dilated cardiomyopathy | | ~5 × 108 | Intracoronary | | Improved |
Perin et al. [237] | Bone marrow MSCs (allogenic) | Chronic heart failure | | 2.5–15 × 107 | Transendocardial | | No change |
HUC-HEART trial [238] | Umbilical cord MSCs (allogenic) versus bone marrow BMNCs (autologous) | Chronic ischemic cardiomyopathy | | 2–20 × 107 | Intramyocardial | | Improved |
Buttler et al. [239] | Bone marrow MSCs (allogenic) | Nonischemic cardiomyopathy | Hypoxic preconditioning | 1.5 × 106/kg | Intravenously | | No change |
TAC-HFT [240] | Bone marrow MSCs versus bone marrow MNCs (autologous) | Chronic ischemic cardiomyopathy | | 2 × 108 | Transendocardial | | No change |
MESAMI 1 [241] | Bone marrow MSCs (autologous) | Ischemic cardiomyopathy | | 4–10 × 107 | Intramyocardial | | Improved |
Anastasiadis et al. [242] | Bone marrow mesenchymal precursor (allogenic) | Chronic ischemic cardiomyopathy | | 1–4 × 106 | Intramyocardial | | Improved |
Chen et al. [243] | Bone marrow MSCs (autologous) | Acute myocardial infarction | | 48–60 × 109 | Intracoronary | ~3 weeks | Improved |
Lee et al. [244] | Bone marrow MSCs (autologous) | Acute myocardial infarction | | ~7 × 107 | Intracoronary | ~4 weeks | Improved |
Gao et al. [245] | Bone marrow MSCs (autologous) | Acute myocardial infarction | | ~3 × 106 | Intracoronary | ~2 weeks | No change |
Chullikana et al. [246] | Bone marrow MSCs (allogenic) | Acute myocardial infarction | | 2 × 106/kg | Intravenously | ~2 days | No change |
Wang et al. [247] | Bone marrow MSCs (autologous) | Acute myocardial infarction | | 2 × 108 | Intracoronary | ~3 weeks | No change |
Rodrigo et al. [248] | Bone marrow MSCs (autologous) | Acute myocardial infarction | | 3–50 × 106 | Intramyocardial | ~3 weeks | Improved |
Gao et al. [249] | Umbilical cord MSCs (allogenic) | Acute myocardial infarction | | 6 × 106 | Intracoronary | ~1 week | Improved |
|